Inhibrx Biosciences, Inc.
SEC CIK 2007919 · INXB · last insider filing 2026-06-04
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Manhard Kimberly | Director | filed 2024 - 2026 |
| Forsyth Douglas | Director | filed 2024 - 2026 |
| Kayyem Jon Faiz | Director | filed 2024 - 2026 |
| Vuori Kristiina MD | Director | filed 2024 - 2026 |
| Lappe Mark | Director · Chief Executive Officer | filed 2024 - 2024 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Matly David | President | filed 2025 - 2026 |
| Deck Kelly | Chief Financial Officer | filed 2024 - 2025 |
| Eckelman Brendan P. | Chief Scientific Officer | filed 2024 - 2024 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.